



ASX RELEASE

15 March 2004

Important New European Patent “Derivatized BioSilicon™”

Global nanotechnology company pSivida Limited (**ASX: PSD**), is pleased to announce that its UK operating subsidiary pSiMedica Limited has been granted a further patent in the important European market.

European Patent 1 175 233 B1 encompasses the use of certain forms of derivatized porous silicon as a biomaterial. These modified forms of BioSilicon™ significantly broaden its utility by enabling a variety of chemical ligands or protein entities to be attached to the surface. In particular, larger protein molecules such as monoclonal antibodies can be tightly adhered to the BioSilicon™ surface. Such antibody molecules can then be used in a diagnostic capacity enabling the BioSilicon™ to selectively measure particular hormones or mediators that are prognostic or diagnostic for disease.

Derivatization of BioSilicon™ is achieved by a variety of methods. The charge and nature of bonding to the BioSilicon™ surface can be regulated to meet the needs of the application by simply varying the derivatization process.

pSivida Managing Director Gavin Rezos said, “This new European Patent is another important addition to an already strong Intellectual Property portfolio and follows the recent patent granted in the US for potential ‘smart’ drug delivery applications of BioSilicon™. This patent further demonstrates the versatility of BioSilicon™ with the derivatized form of the biomaterial potentially providing significant additional functionality for planned diagnostic devices incorporating multilayered porous silicon optical mirrors. Such devices are intended to provide the patient and physician with an “early warning” of disease progress or cancer relapse.”

This European patent follows 6 earlier patent grants in the key jurisdictions of the United Kingdom and United States and further strengthens pSiMedica’s healthcare claims for the BioSilicon™ technology.

The pSiMedica Intellectual Property portfolio consists of 17 patent families, 9 granted patents and over 70 patent applications. pSiMedica owns all of the Intellectual Property (royalty free) for the application of BioSilicon™.

Products protected by patents and patent applications owned by pSiMedica include materials comprising bioactive, resorbable and biocompatible silicon that are of value in the fabrication of new generations of intelligent drug delivery devices, orthopaedic implants and intelligent diagnostic tools.

-ENDS-

Released by:

Josh Mann
Investor Relations
pSivida Limited
Tel: + 61 8 9226 5099
joshuamann@psivida.com.au

NOTES TO EDITORS:

pSivida Limited

pSivida is an Australian-based biotechnology company committed to the biomedical applications of nano-technology and which has as its core focus the development and commercialisation of nano-structured porous silicon (BioSilicon™) in biocompatible and biodegradable forms for use in healthcare through its UK subsidiary pSiMedica Limited, and in conjunction with QinetiQ plc (formerly the UK Government owned Defence Evaluation Research Agency, DERA). As a true 'platform technology', BioSilicon™ has multiple potential applications across the high growth healthcare sector, including controlled drug delivery, brachytherapy, tissue engineering and orthopaedics.

pSivida is listed on the Australian Stock Exchange (**ASX Code: PSD**). pSivida is also listed in Germany on the Frankfurt Stock Exchange on XETRA system, as well as Berlin, Munich and Stuttgart, (German **Symbol: PSI. Securities Code (WKN) 358705**).

For more information visit www.psivida.com.au

pSiMedica Limited (UK)

pSiMedica has identified a biocompatible and biodegradable form of silicon (BioSilicon™). The technology is based on applying a modified form of the silicon chip (porosified or nano-structured silicon) in a variety of healthcare applications, ranging from controlled drug delivery, brachytherapy, tissue engineering and orthopaedics to clinical diagnostics.

pSiMedica's market strength lies in its international management and science team, including former Chairman of SmithKline & French Research, Dr Roger Brimblecombe, former PepTech CEO Dr Roger Aston, and, the world eminent scientist and the inventor of BioSilicon™, Professor Leigh Canham. The Company has access to cutting edge research and development facilities of QinetiQ plc, the largest research and development institution in Europe.

pSiMedica owns the worldwide intellectual property rights to nano-structured porous silicon, known as BioSilicon™, for use in or on humans and is dedicated to realising the potential of porous silicon products in areas such as controlled drug delivery, diagnostics and orthopaedics.

For more information visit www.psimedica.co.uk